Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of $0.36, $0.17 worse than the analyst estimate of $0.53. Revenue for the quarter came in at $126.47 million versus the consensus estimate of $125.67 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.